据证券时报6月5日报道，近日加州大学圣地亚哥分校的一项研究发现，与使用磺酰脲类药物的患者相 比，服用二甲双胍的2型糖尿病女性活到90岁及以上的几率提升了整整30%，还能全身性抗衰，让大脑 年轻6岁左右。二甲双胍逐渐从"降糖老将"进阶为"抗衰黑马"。 科源制药：公司产品盐酸二甲双胍原料药、盐酸二甲双胍片适应症为治疗2型糖尿病，为降糖类药品， 适应症为用于单纯饮食控制不满意的Ⅱ型糖尿病病人，尤其是肥胖和伴高胰岛素血症者。 特一药业：子公司海力制药生产的盐酸二甲双胍缓释片属于双胍类降血糖药，可减少肝脏葡萄糖的生成 量及肠道对葡萄糖的吸收，并通过增加外周葡萄糖的摄取和利用、提高胰岛素敏感性，降低基础和餐后 血糖。 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 证券时报表示，越来越多研究发现，二甲双胍可能不仅能降糖，还可能具备延缓衰老的潜力。而本研究 更是首次将二甲双胍单药治疗与"活到90岁及以上"的长寿可能建立起联系，填补了此前在此领域的研究 空白。二甲双胍可能通过多种机制发挥潜在的抗衰老作用，包括改善胰岛素敏感性、促进细胞修复、抗 炎、抗氧化等。 例如，在2型糖尿病患者中，二甲双 ...

Group 1 - The company is a leading player in the traditional Chinese medicine patch industry, with a stable growth in performance, achieving a revenue of 3.501 billion yuan in 2024 (+5.72%) and a net profit of 723 million yuan (+27.19%) [1] - In Q1 2025, the company reported a revenue of 1.021 billion yuan (+12.29%) and a net profit of 217 million yuan (+13.89%) [1] - The core products showed steady growth, with revenues from patches, tablets, capsules, ointments, and other categories reaching 2.115 billion, 356 million, 752 million, 128 million, and 148 million yuan respectively, with year-on-year growth rates of +3.35%, +35.60%, +5.66%, -7.09%, and -1.20% [1] Group 2 - The company has a strong market presence in external traditional Chinese medicine patches, with annual sales of the Tongluo Pain Relief Patch exceeding 1 billion yuan and the "Two Tigers" series products selling over 1 billion patches annually [1] - The company’s R&D expense ratio for 2024 was 3.76% (+0.45 percentage points), focusing on major diseases and products in orthopedics, respiratory, skin, and digestive systems [2] - The company signed a letter of intent for acquisition with Yingu Holdings Group in December 2024, aiming to acquire a controlling stake in Yingu Pharmaceutical, which aligns with its strategic planning and enhances its product matrix with high-tech nasal sprays and inhalants [2] Group 3 - The company expects net profits for 2025-2027 to be 831 million, 932 million, and 1.056 billion yuan, representing year-on-year growth of +15.0%, +12.2%, and +13.4% respectively [2] - The company maintains a leading brand advantage in the traditional Chinese medicine patch sector, with a solid market share for multiple products, and continues to enhance its product matrix through R&D and acquisitions [2]

Core Viewpoint - The company, Yuekang Pharmaceutical, reported a decline in revenue for 2024, with total revenue of 3.781 billion yuan, a year-on-year decrease of 9.90% [1] Group 1: Operating Performance - The revenue breakdown shows that cardiovascular and anti-infection products generated 2.105 billion yuan and 789 million yuan, respectively, with declines of 20.73% and 22.67% [1][4] - The gross profit margin for the company was 58.76%, with significant differences among product categories; anti-infection products had a gross margin of 6.91%, while cardiovascular products had a margin of 91.08% [1][4] - The company provided a detailed table of sales revenue, volume, unit price, and year-on-year changes for different product types [2][3] Group 2: Revenue Analysis - The decline in cardiovascular product revenue was primarily due to a drop in sales of Ginkgo biloba extract injection, which saw an 8.47% decrease in volume and a reduction in average selling price [5] - The anti-infection product revenue decline was attributed to a shrinking market demand and increased competition, leading to lower sales volumes [5] - Conversely, the digestive system product revenue increased by 123.04% due to improved sales of omeprazole enteric-coated capsules, driven by enhanced marketing strategies [5] Group 3: Gross Margin Analysis - The gross margin differences among product types were influenced by drug classification and centralized procurement impacts [6][7] - Cardiovascular products maintained high margins due to effective market development and production cost management, while anti-infection products faced lower margins due to competitive pricing pressures [7] - The company’s gross margins were compared with industry peers, showing that its margins were generally in line with industry averages [8] Group 4: Sales and Marketing Expenses - The company reported a decrease in marketing and promotion expenses from 1.715 billion yuan in 2023 to 1.242 billion yuan in 2024, a reduction of 27.59% [10][11] - The decrease was attributed to the expansion of centralized procurement, which stabilized sales volumes in public medical institutions, leading to reduced promotional activities [11] - The company’s pricing strategy for major products considered various factors, including R&D costs, market demand, and competition [12] Group 5: Related Party Transactions - The company increased its purchases from Anhui Hengshun Information Technology Co., Ltd. to 221.678 million yuan in 2024, a significant increase from the previous year [18][20] - Anhui Hengshun primarily engages in the production and sale of various pharmaceutical intermediates, and the increase in purchases was due to expanded sales channels and cost advantages [19][20] - The procurement prices from Anhui Hengshun were found to be fair and competitive compared to other suppliers [21]

星标 ★ IPO日报 精彩文章第一时间推送 "一听我是总经理，客户就开始骂，一骂能骂二十分钟，等他停下来，我就问，骂够了能不能告诉我，我错在哪里？" 在掌舵重庆康刻尔制药股份有限公司（证券简称：康刻尔，证券代码：874210，下称"康刻尔制药"，公司目前已启动IPO上市辅导）之前，陈用芳大概这 辈子也没想到她会成为现在的样子。 陈用芳会计专业刚刚毕业，就遇上了全国新旧会计制度交替，大半知识成了"过期品"。 才做财务经理没多久，老板就回了老家休假几个月，把一切账目扔给她。 刚刚应聘进入一家集团公司，就把她下派到亏损工厂进行拯救之旅……似乎在职场的每个节点，陈用芳都要承受巨大的挑战和压力。 三十多年来，陈用芳一直敢闯善干。她把所有的委屈，都化作了满脸春风，以仁爱之心待他人，"让客户当公司的主人"；她把所有的挑战和风险，都转化 成机遇和硕果，面对康刻尔制药的"生死危机"，从容应对，努力创新，拿下难啃的糖尿病市场这块"硬骨头"。 陈用芳的付出得到了认可，也完成了身份的转变——从女会计到身价上亿的董事长，先后获得重庆市"三八红旗手"、十大重庆经济年度创新人物等一系列 荣誉。 日前，面对《国际金融报》记者，在康刻尔制药宽 ...

"一听我是总经理，客户就开始骂，一骂能骂二十分钟，等他停下来，我就问，骂够了能不能告诉我，我错在哪里？" 在掌舵重庆康刻尔制药股份有限公司（证券简称：康刻尔，证券代码：874210，下称"康刻尔制药"，公司目前已启动IPO上市辅导）之前， 陈用芳大概这辈子也没想到她会成为现在的样子。 陈用芳会计专业刚刚毕业，就遇上了全国新旧会计制度交替，大半知识成了"过期品"。 才做财务经理没多久，老板就回了老家休假几个月，把一切账目扔给她。 刚刚应聘进入一家集团公司，就把她下派到亏损工厂进行拯救之旅……似乎在职场的每个节点，陈用芳都要承受巨大的挑战和压力。 三十多年来，陈用芳一直敢闯善干。她把所有的委屈，都化作了满脸春风，以仁爱之心待他人，"让客户当公司的主人"；她把所有的挑战和 风险，都转化成机遇和硕果，面对康刻尔制药的"生死危机"，从容应对，努力创新，拿下难啃的糖尿病市场这块"硬骨头"。 陈用芳的付出得到了认可，也完成了身份的转变——从女会计到身价上亿的董事长，先后获得重庆市"三八红旗手"、十大重庆经济年度创新 人物等一系列荣誉。 日前，面对《国际金融报》记者，在康刻尔制药宽敞的办公室，巨大的泡茶台旁，自信又柔和的陈用 ...